About EndoGastric Solutions

EGS is pioneering incisionless natural
orifice surgery (NOS), the future of surgery

EGS leverages the most current wisdom in gastroenterology and surgery in developing new transoral incisionless procedures and products to advance the state of the art in treating gastrointestinal diseases.

Our first two products, EsophyX and StomaphyX, are based on EGS' proprietary NOS platform technology. Designed specially for performing incisionless reconstructive gastrointestinal procedures, the devices are introduced into the body through the mouth, rather than through an abdominal incision. The advantages of incisionless surgery over laparoscopic or open surgery include shorter hospital stay, reduced patient discomfort, shortened patient recovery, no visible scars, and typically higher patient satisfaction.

The revolutionary TIF (Transoral Incisionless Fundoplication) procedure, made possible through the use of the EsophyX device, effectively treats the cause of Gastroesophageal Reflux Disease (GERD), also known as chronic acid reflux disease. The procedure reconstructs the antireflux barrier at the gastroesophageal junction, restoring the patient’s natural anatomical geometry. A minutely invasive procedure, TIF emulates the invasive gold-standard laporascopic or open procedure used to treat chronic acid reflux disease.

The innovative StomaphyX device is used for performing incisionless gastric pouch reduction post bariatric surgery. Without any external incisions or internal dissection, StomaphyX creates durable, full thickness tissue folds, or plications, in the gastric pouch to reduce its total volume, typically as much as 50-70%. This slows the flow of food into the intestine, returning the feeling of satiety, which when combined with a healthy eating and exercise program can lead to weight loss.

C01797-01 A